Literature DB >> 13130092

Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis.

Anna M Joy1, Christian E Beaudry, Nhan L Tran, Francisco A Ponce, David R Holz, Tim Demuth, Michael E Berens.   

Abstract

Glioma cells that migrate out of the main tumor mass into normal brain tissue contribute to the failure of most gliomas to respond to treatment. Treatments that target migratory glioma cells may enhance the therapeutic response. Multiple lines of evidence suggest that suppression of apoptosis accompanies activation of the migratory phenotype. Here, we determine whether migration and apoptosis are consistently linked in glioma cells and whether manipulation of migration influences cytotoxic therapy-induced apoptosis. Camptothecin and Trail-induced apoptosis were decreased 2-5-fold in actively migrating glioma cells relative to migration-restricted cells. Consistent with a mechanistic link between migration and apoptosis, the dose-response for stimulation of migration on laminin was inversely proportional to apoptosis induction. Treatment of glioma cells with migration inhibitors alone had little effect on basal rates of apoptosis and had little effect on Trail-induced or camptothecin-induced apoptosis in migration-restricted cells. By contrast, migration inhibitors increased camptothecin and Trail-induced apoptosis in actively migrating glioma cells. Migrating glioma cells have increased amounts of phosphorylated Akt and its downstream substrate glycogen synthase kinase-3 relative to migration restricted cells. Treatment of migrating cells with a specific inhibitor of phosphoinositide 3-kinase (PI3-K), LY294002, blocked the phosphorylation of Akt and increased the sensitivity to apoptosis. LY294002 had no effect on the migration of restricted cells. This suggests that migrating glioma cells activate the PI3-K survival pathway, protecting migrating cells from apoptosis. Taken together, these data provide support for a link between migration and apoptosis in glioma cells. In addition, evidence indicates that treatment with migration inhibitors, while not affecting apoptosis-induction in migration-restricted cells, can sensitize migrating glioma cells to cytotoxic agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13130092     DOI: 10.1242/jcs.00712

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  64 in total

1.  Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

Authors:  Morris D Groves; Vinay K Puduvalli; Charles A Conrad; Mark R Gilbert; W K Alfred Yung; Kurt Jaeckle; Vivien Liu; Kenneth R Hess; Kenneth D Aldape; Victor A Levin
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

Review 2.  Roles of NG2 glial cells in diseases of the central nervous system.

Authors:  Jian-Ping Xu; Jie Zhao; Shao Li
Journal:  Neurosci Bull       Date:  2011-12       Impact factor: 5.203

3.  Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells.

Authors:  Lara Macchioni; Magdalena Davidescu; Miriam Sciaccaluga; Cristina Marchetti; Graziella Migliorati; Stefano Coaccioli; Rita Roberti; Lanfranco Corazzi; Emilia Castigli
Journal:  J Bioenerg Biomembr       Date:  2011-07-21       Impact factor: 2.945

4.  Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells.

Authors:  Magdalena Davidescu; Miriam Sciaccaluga; Lara Macchioni; Roberto Angelini; Patrizia Lopalco; Maria Grazia Rambotti; Rita Roberti; Angela Corcelli; Emilia Castigli; Lanfranco Corazzi
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

5.  The tyrosine kinase pyk2 promotes migration and invasion of glioma cells.

Authors:  Christopher A Lipinski; Nhan L Tran; Emmanuel Menashi; Carole Rohl; Jean Kloss; R Curtis Bay; Michael E Berens; Joseph C Loftus
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 6.  The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas.

Authors:  Florence Lefranc; Robert Kiss
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

7.  Insulin resistance in striated muscle-specific integrin receptor beta1-deficient mice.

Authors:  Haihong Zong; Claire C Bastie; Jun Xu; Reinhard Fassler; Kevin P Campbell; Irwin J Kurland; Jeffrey E Pessin
Journal:  J Biol Chem       Date:  2008-12-08       Impact factor: 5.157

8.  Neuropeptides of the VIP family inhibit glioblastoma cell invasion.

Authors:  Stéphanie Cochaud; Annie-Claire Meunier; Arnaud Monvoisin; Souheyla Bensalma; Jean-Marc Muller; Corinne Chadéneau
Journal:  J Neurooncol       Date:  2015-01-07       Impact factor: 4.130

9.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

10.  STAT3 silencing inhibits glioma single cell infiltration and tumor growth.

Authors:  Maike Priester; Ekaterini Copanaki; Vida Vafaizadeh; Sandra Hensel; Christian Bernreuther; Markus Glatzel; Volker Seifert; Bernd Groner; Donat Kögel; Jakob Weissenberger
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.